ABBOTINDIA vs GKSL: Stock Comparison
Abbott India Limited vs Gujarat Kidney & Super Speciality Ltd
Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings
Abbott India Limited is the larger company by market capitalisation. Abbott India Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of Abbott India Limited and Gujarat Kidney & Super Speciality Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ABBOTINDIA | GKSL |
|---|---|---|
| Sector | Healthcare | — |
| Industry | Pharmaceuticals | — |
Price
| Metric | ABBOTINDIA | GKSL |
|---|---|---|
| Live Price | ₹28,005 | ₹128.2 |
| Day Change | -0.1% | 0.71% |
| Volume | 10,811 | 73,624 |
| 52-Week High | ₹35,310 | ₹148.34 |
| 52-Week Low | ₹25,150 | ₹98.36 |
| Distance from 52W High | -20.69% | -13.58% |
Valuation
| Metric | ABBOTINDIA | GKSL |
|---|---|---|
| Market Cap | ₹59,598 Cr | ₹1,013 Cr |
| P/E Ratio | 38.38x | 65.23x |
| P/B Ratio | 12.48x | 4.01x |
| EPS | ₹731.52 | ₹1.97 |
| Book Value | ₹2,246.69 | ₹32 |
| Dividend Yield | 1.82% | 0% |
Growth
| Metric | ABBOTINDIA | GKSL |
|---|---|---|
| Revenue Growth (TTM YoY) | 6.5% | 0% |
| EPS Growth (TTM YoY) | 7.6% | 0% |
| Qtr Sales Growth | 6.54% | 213% |
| Qtr Profit Growth | 7.6% | 294% |
Profitability & Leverage
| Metric | ABBOTINDIA | GKSL |
|---|---|---|
| ROE | 34.5% | 11.1% |
| ROCE | 44.9% | 14.5% |
| Net Margin | 22.4% | 20.5% |
| Operating Margin | 27.3% | 32.8% |
| Debt to Equity | 0.04x | 0.12x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | ABBOTINDIA | GKSL |
|---|---|---|
| Promoter Holding | 74.99% | 71.45% |
| FII Holding | 0.26%▲ 0.08 pp | 4.88%▼ 5.59 pp |
| DII Holding | 8.93%▼ 0.07 pp | 0.56%▼ 1.11 pp |
| Public Holding | 15.81%▼ 0.02 pp | 23.1%▲ 6.7 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Abbott India Limited and Gujarat Kidney & Super Speciality Ltd.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.